At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19 enrolled
Drug / intervention
Global gene expression profiles obtained from synovial biopsies.procedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients (MEAS Study)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain·interventional·Posted Nov 27, 2020·Updated Sep 21, 2023
In Brief
A clinical study evaluating Global gene expression profiles obtained from synovial biopsies. for Psoriatic Arthritis. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This study assess the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after an immunomodulator agent (Apremilast) in patients with active psoriatic arthritis who are naive to treatment with a conventional synthetic DMARDs (such as methotrexate).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesBelgium
CollaboratorsAmgen
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedNov 2020
Primary CompletionJan 2023
Study CompletionFeb 2023
TodayJul 2026
First PostedNov 27, 2020
Enrollment StartNov 12, 2020
Primary CompletionJan 10, 2023
Study CompletionFeb 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.6 years ago
Interventions
Global gene expression profiles obtained from synovial biopsies.procedure
Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.